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Abstract
Background—Spending on physician-administered drugs is high and uses not approved by the 
U.S. Food and Drug Administration (FDA) are frequent. While these drugs may be targets of 
future policy efforts to rationalize use, little is known regarding how physicians respond to 
emerging safety and effectiveness evidence.
Study objective—We analyzed changes in bevacizumab (Avastin™) use for breast cancer in 
response to its market launch (Feb-2008), two FDA meetings reviewing data suggesting that its 
risks exceed its benefits (July-2010, June-2011), and the FDA’s withdrawal of approval 
(Nov-2011).
Data—Data from a population-based audit of oncologists’ prescribing (IntrinsiQ Intellidose) were 
used to measure the monthly number of breast cancer patients treated with bevacizumab January, 
2008-April,2012.
Methods—The number of bevacizumab patients following each regulatory action was estimated 
using negative binomial regression, compared with patients before the first FDA meeting, 
adjusting for cancer stage, treatment line, patient age and outpatient office affiliation.
Results—Bevacizumab use for breast cancer increased significantly after FDA approval. 
Following all regulatory actions, there was a 65% decline (95%CI=64%-65%) in use compared 
with the period before the first meeting. The largest decline was in the six-month period following 
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the first meeting (37%, 95%CI=28%-47%). The rate of decline did not differ by patient or cancer 
characteristics and differed minimally by office affiliation.
Discussion—Bevacizumab use for breast cancer declined dramatically after FDA meetings and 
regulatory actions, a period without changes in guideline recommendations or insurance coverage. 
Physicians appear responsive to emerging evidence concerning physician-administered drug safety 
and effectiveness.
Introduction
Physician-administered prescription drugs are an increasingly important component of total 
United States (U.S.) drug expenditures.1 Medicare is the dominant payer for many 
physician-administered drugs.2 Recent evidence suggests thirty percent of these drugs’ use 
in 2010 was for clinical indications not approved by the Food and Drug Administration 
(FDA).3 Thus, these drugs may be targets of future policy initiatives intending to rationalize 
their use.
The impact of initiatives to improve drug prescribing is dependent upon the degree to which 
physicians respond to emerging evidence. Prior empirical evidence has largely evaluated 
regulatory communications impact on oral drug utilization,4-9 with most studies identifying 
declines in drug use after safety or effectiveness concerns emerge.4,5,7,9 These studies have 
primarily focused on drugs prescribed in primary care settings.4,7,9 Yet, physicians’ 
responses to emerging drug safety and effectiveness evidence are likely related to the 
institutional setting where they are administered,4,6,10,11 since the income for some specialty 
physicians, such as oncologists, may be closely tied to drugs administered in outpatient 
offices.2,3,12-14 Oncologists treating patients in private practice outpatient settings thus face 
direct financial incentives to closely follow the emerging evidence regarding physician-
administered drugs.1,2,12-15 Only one study we are aware of examines trends in the use of a 
physician-administered drug following changes in evidence supporting its clinical use.5 In 
that study, use of anthracycline-based chemotherapy declined sharply and taxane-based 
chemotherapy increased among ambulatory breast cancer patients immediately following 
scientific presentations of two well-publicized clinical trials in 2005.
The objective of this study is to examine trends in the use of a physician-administered 
chemotherapy, bevacizumab (Avastin™, Genentech Inc.) for breast cancer, between its 
provisional FDA approval and subsequent regulatory actions (Figure 1).
Bevacizumab was the first anti-angiogenic drug approved by FDA for treatment of 
metastatic colorectal cancer (2004) and for unresectable, locally-advanced, recurrent or 
metastatic non-squamous non-small cell lung cancer (2006).16-18 In February 2008, the FDA 
granted accelerated provisional approval for bevacizumab as first-line therapy for metastatic 
human epidermal growth factor receptor-2 (HER-2) negative breast cancer.18-21
The FDA’s provisional approval of bevacizumab for this indication was based on early 
results from the Eastern Cooperative Oncology Group (ECOG) E2100 trial indicating an 
improvement in progression-free survival (PFS).19 The FDA required Genentech to provide 
subsequent data to confirm the clinical benefits for PFS and overall survival (OS).20 Longer 
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term follow-up of the E2100 trial, the Avastin and Docetaxel (AVADO) trial22 and the 
Regimens in Bevacizumab for Breast Oncology (RIBBON-1) trial,23 showed modest 
improvements in PFS but failed to demonstrate an improvement in OS with the addition of 
bevacizumab to standard chemotherapy among breast cancer patients with metastatic 
disease. Upon reviewing the trial data in July 2010, the FDA’s Oncologic Drugs Advisory 
Committee (ODAC) voted to remove the indication for breast cancer from bevacizumab’s 
label, and in December 2010 the FDA announced its plans to withdraw approval for breast 
cancer.20,24 This announcement was followed by a June 2011 hearing where ODAC voted 
again to rescind bevacizumab’s breast cancer indication.20 FDA revoked bevacizumab’s 
indication for breast cancer on November 18, 2011 (Figure 1).25
METHODS
Data
We employed data from the Intellidose software system (AmerisourceBergen Specialty 
Group) for the analysis.3,26,27 During the study period, Intellidose was used as the exclusive 
computerized method of outpatient chemotherapy order entry and billing for 122 medical 
oncology practices, comprising 570 oncologists across 35 states. These outpatient offices 
were largely physician-owned or affiliated with community hospitals/clinics. The number of 
practices remained stable and the system did not employ clinical decision aids during the 
study period. For each patient initiating chemotherapy, practice staff recorded date of birth, 
sex, cancer type, cancer stage,28 diagnosis date and chemotherapy date.
Sample Selection
Women with a primary diagnosis of breast cancer who were treated with bevacizumab 
between February 2008 and April 2012 were identified. Patients with missing cancer stage, 
stage 0 cancers and those participating in a clinical trial (<1% in each month) were excluded 
from analysis.
Variables
The monthly number of patients treated with bevacizumab was identified; if a patient 
received more than two doses in a month, it was counted only once. Each patient’s cancer 
stage (stage IV (metastatic) vs. stages I-III (non-metastatic)) and treatment line (first vs. 
second or later) were characterized. We examined patterns of bevacizumab use by outpatient 
office affiliation (academic, community hospital/clinic, and private), since oncologist 
revenues in private practice have been most closely tied to chemotherapy use.14,29 We also 
investigated use by patient age (≥sixty-five vs. <sixty-five), because changes in use among 
those over sixty-five years of age could be related to Medicare’s coverage policies.12,14,29
Study Periods
Five distinct time segments were created based on the FDA regulatory actions regarding 
bevacizumab and breast cancer: (1) Post-provisional approval but pre-ODAC period: 
February 2008-May 2010; (2) First ODAC meeting: June 2010-November 2010; (3) FDA 
announcement of plans to withdraw approval: December 2010-May 2011; (4) Second 
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ODAC meeting: June 2011-October 2011; and (5) FDA withdrawal of approval: November 
2011-April 2012 (Figure 1).
Analyses
The outcome for all analyses was the number of patients treated monthly with bevacizumab 
during the study period. A generalized negative binomial model was used to estimate 
changes in average monthly bevacizumab use compared with the pre-ODAC period, 
adjusting for time since approval, quarter, patient and cancer characteristics and office 
affiliation.30-32 The predicted number of patients treated monthly with bevacizumab was 
calculated based on model results. We present average predicted patient counts per period 
and percent declines per period compared with pre-ODAC meeting patient counts with 95% 
confidence intervals (95% CI). Tests of statistical significance in average percent declines 
compared with pre-ODAC levels were based on two-sided Student t-tests with unequal 
variances assumed derived from model estimates; p-values <0.05 were considered 
statistically significant.
Sensitivity analysis
We re-estimated percent declines per period compared with pre-ODAC meeting patient 
counts stratified by covariates to detect policy relevant differences in bevacizumab use 
trends by patient and cancer characteristics and office affiliation, and we tested for statistical 
significance of interactions using two-sided Student T-tests. We re-estimated models using 
counts of administrations (instead of patients) as the main outcome variable, since this is the 
typical billing unit for insurer reimbursement.
RESULTS
During the study period, most patients treated with bevacizumab had metastatic disease, 
received bevacizumab as second or later line therapy, were younger than sixty-five years, 
and were treated in a private practice or community hospital/clinic (Table 1).
Upon FDA approval through the quarter preceding the first ODAC meeting, there was a 54 
percent increase in the average number of breast cancer patients who were treated with 
bevacizumab in a given month, from 16,280 to over 24,000 patients (Figure 2.a). These 
increases are concentrated among patients with metastatic disease (Figure 2.a), second or 
later line of therapy (Figure 2.b), under sixty-five years of age (Figure 2.c) and those treated 
in private practice (Figure 2.d). Declines were observed in the number of breast cancer 
patients using bevacizumab coincident with the first ODAC meeting, continuing through 
2012 (Figures 1.a-d).
Table 2 reports the average predicted number of patients and estimated percent declines in 
patients treated with bevacizumab in each period compared with that predicted in the pre-
ODAC period based on model results. In the pre-ODAC period a monthly average of 23,682 
patients used bevacizumab. From the pre-ODAC period to the period following FDA 
withdrawal of breast cancer approval in December 2011, there was a 65 percent decline 
(95%CI=64%-65%) in the monthly number of patients treated with bevacizumab. The 
largest declines observed were during the six-month period following the initial ODAC 
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meeting (July 2010), during which average monthly bevacizumab use declined by 37 
percent from the pre-advisory period (95%CI=28%-47%).
Results of the sensitivity analyses were similar to those estimated in the main models. 
Associations were non-significantly different between all patient and cancer subgroups at 
traditional levels (P>0.05 for interactions of period with patient age, cancer stage, treatment 
line). The magnitude of the percentage decline in patients treated with bevacizumab in 
academic medical centers following all regulatory actions was greater than that estimated for 
patients treated in other settings (P-value<0.001). However, the absolute difference between 
these groups was small (67% decline in academic medical centers vs. 64% in community 
hospitals/clinics and 65% in private practices).
4. DISCUSSION
This study is among the first to examine trends in prescribing of physician-administered 
drugs following changes in supportive evidence and subsequent regulatory actions. In a 
population-based audit of oncologists, bevacizumab use declined 65 percent after regulatory 
actions. The largest decline (37 percent) occurred following the FDA’s initial evidence 
review in July 2010.
While changes in bevacizumab use in response to emerging safety and effectiveness 
evidence could be related to changes in guideline recommendations and/or insurers’ 
coverage policies, we did not find evidence to suggest these changes occurred. There was no 
change in the guideline recommendation by the National Comprehensive Care Network 
(NCCN), and Medicare did not alter reimbursement policy during the study period.3,21 
Communications with the medical directors of two large commercial insurers, (Wellpoint 
(34 million members)33 and Aetna (18 million members))34 also reported no changes were 
made to their coverage of bevacizumab for breast cancer.
Our findings suggest oncologists responded quickly to emerging evidence about the limited 
benefit to risk trade-off of bevacizumab for breast cancer even before the FDA withdrew 
approval for this indication and without concomitant changes to clinical guidelines or 
insurers’ coverage policies. Moreover, these changes likely represent a lower bound on 
bevacizumab use in response to regulatory actions, since the monthly patient counts 
included both those initiating and continuing bevacizumab treatment. Sample characteristics 
were consistent with other published reports regarding use of bevacizumab-based breast 
cancer treatment over this period, providing some additional assurance of the data’s external 
validity.18,35,36 Interestingly, after additional evidence emerged we observed slightly larger 
declines in use by physicians practicing in academic medical centers vs. other settings, but 
not by other patient or cancer characteristics.
The magnitude of the decline in bevacizumab use we document is larger than that reported 
in primary care contexts,4,8,9 but similar to declines estimated for anthracycline based 
chemotherapy for breast cancer5 and for hormone replacement therapy use after the 
publication of the Women’s Health Initiative.37 The magnitude of the estimated decline 
might be related to the larger number of regulatory actions targeting bevacizumab.4 Future 
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work is needed to document whether these responses generalize to the release of new 
evidence in the treatment of other cancers or the use of other physician-administered drugs.
Important questions remain regarding the clinical implications of the substantial declines in 
bevacizumab use following regulatory actions we observed.The continued recommendation 
of bevacizumab for breast cancer in the NCCN guidelines suggests that experts still believe 
bevacizumab has value in treating metastatic breast cancer despite the FDA’s actions.21 
Future observational studies might leverage area-level differences in the changes in use of 
bevacizumab to assess whether changes in use of bevacizumab led to better outcomes for 
patients.
The analyses have several limitations. While breast cancer incidence overall and by stage 
was stable between 2005 and 2009,40 the declines we estimate may be partially attributable 
to changes in the mix of cancer types amenable to bevacizumab treatment. Also, although 
IntrinsiQ represents a large number of practices located throughout the U.S., practices using 
Intellidose may be more technologically savvy and/or guideline adherent compared to 
average practices.3,13,26 Unfortunately, we were unable to assess changes in patient or 
physician preferences or changes in bevacizumab promotion, nor did we have data to 
examine trends in prescribing variations by individual physicians or outpatient office 
practices. Some patients under the age of sixty-five may have received insurance coverage 
by Medicare during the study period.
In sum, bevacizumab use for breast cancer treatment declined dramatically following FDA 
regulatory actions in July 2010 and thereafter. Unlike previous work in primary care 
settings, declines in use appear unrelated to changes in guideline recommendations or 
insurance coverage. Declines in bevacizumab use suggest oncologists are responsive to 
emerging evidence regarding physician-administered drug safety and effectiveness.
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Timeline of events affecting bevacizumab’s United States Food and Drug Administration 
(FDA) approval for the treatment of breast cancer, January 2008-December 2011
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a-d. Trends in the number of breast cancer patients treated with bevacizumab, February 
2008-April 2012.
a. Trends in breast cancer patients treated with bevacizumab overall and by cancer stage
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b. Trends in breast cancer patients treated with bevacizumab by line of therapy
c. Trends in breast cancer patients by age
d. Trends in breast cancer patients treated with bevacizumab by outpatient office affiliation
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